Galapagos is a Belgian clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Our mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, we discover which proteins ('targets') play a key role in causing diseases such as inflammatory bowel disease. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms. Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.
